VIA
CRBU icon

Vident Investment Advisory’s Caribou Biosciences CRBU Stock Holding History

Vident Investment Advisory’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,673
Closed -$83.2K – 1222
2023
Q1 		$83.2K Buy
15,673
+192
+1% +$1.2K ﹤0.01% 1178
2022
Q4 		$97.2K Sell
15,481
-2,831
-15% -$25.2K ﹤0.01% 1110
2022
Q3 		$193K Buy
18,312
+1,833
+11% +$17.1K 0.01% 1007
2022
Q2 		$89K Sell
16,479
-55,887
-77% -$427K ﹤0.01% 1207
2022
Q1 		$664K Buy
72,366
+12,060
+20% +$127K 0.02% 838
2021
Q4 		$910K Buy
+60,306
New +$1.17M 0.02% 740

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vident Investment Advisory's CRBU Position: Q2 2023 in Review

Vident Investment Advisory sold out of Caribou Biosciences (CRBU) in Q2 2023, closing a stake of 15,673 shares — an estimated $83.2K sold.

Vident Investment Advisory first reported a position in CRBU in Q4 2021 and held it in 6 quarters. The position peaked at $910K in Q4 2021. 121 funds tracked by Wall St. Rank hold CRBU as of Q2 2023.

  • Vident Investment Advisory reported no remaining Caribou Biosciences position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 15,673 Caribou Biosciences shares in Q2 2023, an estimated $83.2K.
  • Vident Investment Advisory first reported a position in Caribou Biosciences in Q4 2021 and held it in 6 quarters.
  • Vident Investment Advisory's Caribou Biosciences position peaked at $910K in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.